Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

0 100 200 300 400 500 600 700 0 6 12 18 24 Time post - dose (hours) 560mg QD 0 100 200 300 400 500 600 700 0 6 12 18 24 Time post - dose (hours) 100mg QD Adapted from Advani et al ., JCO, 2013 ▪ Cmax and AUC of zanubrutinib at 80mg QD appear to be similar to those of ibrutinib at 560mg ▪ Free drug exposure of zanubrutinib at 40mg QD appears to be comparable to that of ibrutinib at 560mg ▪ Distinct profile compared to acalabrutinib which has a short half - life (1 hour) 2 and lower in vitro BTK inhibition IC50 1 - 4 ▪ In vitro BTK inhibition IC50 relative to ibrutinib: 1.11 (zanubrutinib) and 3.42 – 7.23 (acalabrutinib) zanubrutinib ibrutinib acalabrutinib Adapted from Byrd et al. , NEJM, 2016 0 100 200 300 400 500 600 700 0 6 12 18 24 Plasma Concentration (ng/mL) Time post - dose (hours) 40mg QD 80mg QD 160mg QD 320mg QD Ph3 Dose: • 160mg BID Ph3 Dose: • 100mg BID Approved Doses: • 420mg QD for CLL/WM • 560mg QD for MCL/MZL Data from separate Ph1/2 trials^ 24 Zanubrutinib – Pharmacokinetics Profile ^Cross - trial comparison Source: 1. Tam et al., ASH, 2015; 2. Byrd et al., NEJM, 2016; 3. Lannutti et al., AACR, 2015, 4. BeiGene data

 


© 2016 BeiGene. All Rights Reserved.